Preclinical validation of a novel cancer immunotherapeutic

Epsilogen（前身为IGEM Therapeutics）正在开发一种新的HER2靶向抗体EPS 201，该抗体是根据许多关键属性选择的，这些属性使其与上市竞争对手区分开来。该项目旨在通过开发产品质量检测、GLP毒理学和疗效的体内模型以及用于GMP进展的生产细胞系，使EPS 201更接近临床。IgE提供了一种完全独特的抗癌作用模式，使我们的产品能够与基于IgG的疗法明显区分开来。

Epsilogen (formerly IGEM Therapeutics) is developing a novel HER2-targeted antibody EPS 201, selected on a number of key attributes that sets it apart from marketed competitors. The project seeks to move EPS 201 closer to the clinic through development of product quality assays, _in vivo_ models for GLP toxicology and efficacy, and a manufacturing cell line for progression to GMP. IgE provides a completely unique anti-cancer mode of action which enables our products to be clearly differentiated from IgG-based therapies.